Nucleus RadioPharma, a development, manufacturing, and supply chain organization for radiopharmaceuticals reported a $56 million Series A funding round led by Eclipse and GE HealthCare with participation from Echo Global, Fox Chase Cancer Center, Granger Management, Mayo Clinic, Mercy Health, and University of Missouri. With the funding, Nucleus RadioPharma will establish multiple new manufacturing facilities around the country, including Rochester, Minnesota, near Mayo Clinic, and build novel technology for the development, manufacturing, and distribution of radiopharmaceuticals.
Radiopharmaceuticals offer a highly targeted approach to a wide variety of cancer types and stages.

In addition to its manufacturing capabilities, Nucleus RadioPharma will shape the development of a new supply chain network designed to move, track, and deliver materials to patients faster and more efficiently. This network will cover the entire process, from identifying target molecules and testing treatments to supporting regulatory approvals and delivering patient-ready medication. To enable global logistics and distribution of these therapies, the company is developing novel software and hardware technologies.

“Theranostic radiopharmaceuticals are offering promise for millions who currently have limited treatment options,” said Charles Conroy, CEO of Nucleus RadioPharma. “As truly targeted therapies, these drugs are proving not only to be highly effective but also to maintain a superior safety profile. This funding advances the reach and impact of these life-saving agents, allowing for therapies that can be mass-produced, and offers hope to those with few alternatives.”

In a statement, Nucleus RadioPharma said that it is positioned to expedite the availability of targeted radiopharmaceutical therapies through several ongoing partnerships and collaborations. These will enable rapid initiation of clinical trials, full support for formulation, analytical method development, regulatory guidance, and commercial manufacturing.